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The contribution of cigarette smoking to sporadic colorectal cancer may differ according to molecular aspects of
the tumor or according to glutathione S-transferase M1 (GSTM1) or glutathione S-transferase T1 (GSTT1)
genotype. In the prospective Netherlands Cohort Study on Diet and Cancer, adjusted incidence rate ratios for
1986–1993 were computed for overall colorectal cancer, tumors with and without adenomatous polyposis coli
(APC) mutations, and tumors with and without human mut-L homologue 1 (hMLH1) expression, according to
cigarette smoking characteristics (661 cases, 2,948 subcohort members). Case-only analyses were performed to
estimate odds ratios for interaction between cigarette smoking and GSTM1 and GSTT1 genotypes. In comparison
with never smokers, a high smoking frequency increased the risk of colorectal cancer (for a ﬁve-cigarette/day
increment, incidence rate ratio (IRR) ¼ 1.07, 95% conﬁdence interval (CI): 1.03, 1.12), and this association was
stronger in 371 tumors without a truncating APC mutation (IRR ¼ 1.11, 95% CI: 1.05, 1.17). Long-term smoking
was associated with lack of hMLH1 expression in 56 tumors (for a 10-year increment, IRR ¼ 1.17, 95% CI: 1.00,
1.37). No statistically signiﬁcant interactions between smoking and GSTM1 or GSTT1 genotype were observed.
These results indicate that cigarette smoking is associated with risk of colorectal cancer, and this association may
depend on molecular characteristics of the tumor as deﬁned by APC mutation and hMLH1 expression status.
adenomatous polyposis coli; colorectal neoplasms; glutathione transferase; neoplasm proteins; polymorphism,
genetic; smoking
Abbreviations: APC, adenomatous polyposis coli; CI, conﬁdence interval; GSTM1, glutathione S-transferase M1; GSTT1,
glutathione S-transferase T1; hMLH1, human mut-L homologue 1; IRR, incidence rate ratio; PALGA, Pathologisch
Anatomisch Landelijk Geautomatiseerd Archief; PCR, polymerase chain reaction.
Long-term smoking is a potential risk factor for colorectal
cancer (1, 2). Long-term, heavy smoking has consistently
been found to be associated with colorectal adenomas (3),
whereas associations with colorectal carcinomas have been
inconsistent (3). The observed association between cigarette
smoking and both small and large adenomas led to the
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current assumption that tobacco smoking is involved in
early tumorigenesis.
If cigarette smoking is an early event in tumorigenesis,
long-term follow-up should show a positive association
between smoking and colorectal cancer when the extensive
lag time (over 30 years) for the carcinogenic process is taken
into account (3). Indeed, Giovannucci et al. (4, 5) found
a twofold increase in risk of colorectal cancer after 35 years
of smoking. This finding was supported by a report from
another long-term US cohort study (6) but not by other
reports (7–9).
Most sporadic colorectal cancers are thought to arise
through underlying genetic pathways, which involve
aberrations in a number of genes, as described by Fearon
and Vogelstein (10). Inactivation of the adenomatous
polyposis coli (APC) tumor suppressor gene is thought to
be a key event early in colorectal tumorigenesis. This is
underscored by findings of somatic mutations in the
mutation cluster region of APC, leading to a truncated and
therefore inactive APC protein in the majority of sporadic
colorectal adenomas and carcinomas (11–13). We pre-
viously reported on the occurrence of a large number of
mutations in the mutation cluster region of the APC gene;
however, these would lead to a truncated APC protein in just
37 percent of patients (14). Because smoking is thought to
be involved in the early stages of colorectal tumorigenesis,
smoking may be associated with mutations in the APC gene.
This is supported by results from rodent studies in which
benzo(a)pyrene was found to induce G/T transversions
and N-nitrosamines were found to induce G:C/A:T
transitions in ras oncogenes (15), both of which are
important constituents of cigarette smoke.
Colorectal cancer can be divided broadly into two
subgroups based on genomic instability. Whereas the
majority of sporadic colorectal tumors are chromosomally
unstable, a smaller subset (~10–15 percent) exhibit loss of
mismatch repair as manifested by microsatellite instability.
In approximately 90 percent of microsatellite-unstable
tumors, absence of human mut-L homologue 1 (hMLH1)
expression was observed (16). Studies have shown that
microsatellite instability and mutations in the APC, TP53,
and K-ras genes occur almost mutually exclusively (17–19),
which suggests that these aberrations represent separate
pathways. The risk of smoking may be associated with the
specific subset of colorectal tumors displaying microsatel-
lite instability. Cigarette smoking was found to be associ-
ated with microsatellite-unstable colorectal tumors in three
case-control studies (20–22), whereas another case-control
study could not confirm this (23).
Persons with a homozygous deletion of the glutathione-
S-transferase M1 (GSTM1) gene or the glutathione
S-transferase T1 (GSTT1) gene have no enzyme expression
and may therefore be at an increased risk of developing
colorectal cancer when exposed to carcinogens from
cigarette smoke. However, previous reports on the interac-
tion between tobacco smoking and GSTM1 and/or GSTT1
have not shown a relation between smoking and genotype
(24–28). In the absence of data on the GSTM1 and GSTT1
genotypes in controls, a case-only design provides an
efficient means of estimating possible interactions with
a greater precision than can be obtained from case-control
studies (29).
Our aim in this analysis was to investigate associations
between cigarette smoking and overall colorectal cancer
risk in a prospective cohort study. In addition, we studied
associations between smoking and (specific) mutations in
the APC gene and absence of hMLH1 expression, which are
thought to represent distinct mechanisms involved in co-
lorectal carcinogenesis. We evaluated possible interactions
between cigarette smoking and the GSTM1 and GSTT1
genotypes in a nested case-only design.
MATERIALS AND METHODS
Study population
The prospective Netherlands Cohort Study on Diet and
Cancer was initiated in September 1986. The study design
has been described in detail elsewhere (30). At baseline,
a total of 58,279 men and 62,573 women between the ages
of 55 and 69 years completed a self-administered food
frequency and lifestyle questionnaire. The study population
was derived from 204 municipal population registries
throughout the Netherlands.
Incident cancer cases are identified by monitoring of the
entire cohort for cancer occurrence through annual record
linkage to the Netherlands Cancer Registry (nine regional
cancer registries throughout the Netherlands) and the
Pathologisch Anatomisch Landelijk Geautomatiseerd Ar-
chief (PALGA), a nationwide network and registry of histo-
and cytopathology (31). Together, the Netherlands Cancer
Registry and PALGA provide nearly 100 percent coverage
of the municipalities included in the Netherlands Cohort
Study on Diet and Cancer.
Accumulation of person-time in the cohort was estimated
through biennial vital status follow-up of a subcohort of
3,500 men and women who were randomly selected after
baseline exposure measurement (31). Cases with prevalent
cancer other than nonmelanoma skin cancer were excluded
from the subcohort, resulting in a subcohort of 3,346 men
and women. No subcohort members were lost to follow-up.
The first 2.3 years of follow-up were excluded because of
incomplete nationwide coverage of PALGA in some of the
municipalities included in the Netherlands Cohort Study on
Diet and Cancer during that period. Within this period, 83
subcohort members died or were diagnosed with cancer other
than nonmelanoma skin cancer, leaving 3,263 subcohort
members for analysis. From 1989 to 1994, 929 incident cases
of histologically confirmed colorectal cancer were identified
within the cohort, of which 819 could also be linked to
a PALGA report of the lesion (figure 1). The PALGA reports
were used to identify and locate tumor tissue from eligible
colorectal cancer patients in Dutch pathology laboratories.
Tissue samples and DNA isolation
Tumor material from colorectal cancer patients was
collected after approval by the Ethical Review Board of
Universiteit Maastricht, PALGA, and the Netherlands Cancer
Registry. Tissue samples from 819 colorectal cancer patients
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were localized in 54 pathology laboratories throughout
the Netherlands. Forty-four (5 percent) tumor tissue samples
could not be retrieved. Of 775 available tissue samples,
737 (95 percent) contained sufficient tumor material for
molecular analyses (figure 1). DNA isolation has been
described in detail elsewhere (32). Genomic DNA was
extracted from macrodissected tumor tissue using proteinase
K. DNA concentration and purity were measured in
a spectrophotometer at 260 nm and 280 nm.
APC mutation analysis
The majority of somatic mutations in the APC gene occur
within the mutation cluster region (codons 1286–1520).
Analysis of specific mutations in the mutation cluster region
was performed on archival adenocarcinoma DNA by
amplification of the mutation cluster region in four over-
lapping DNA fragments in a nested polymerase chain
reaction (PCR), followed by direct sequencing of purified
fragments as previously described (14). The detection limit
was 5 percent mutated DNA, and duplicate experiments
revealed good reproducibility (85 percent) (14). From 72 of
the 737 patients with a sufficient DNA yield, one or more
fragments of the mutation cluster region could not be
amplified; these patients were excluded from this study,
leaving 665 patients (90 percent) available for subsequent
analyses (figure 1).
hMLH1 immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were sectioned
at 4 lm and included tumor tissue with normal adjacent
mucosa. Endogenous peroxidase activity was blocked with
3 percent hydrogen peroxide. Slides were submitted to
microwave antigen retrieval in 1 mM ethylenediaminetetra-
acetic acid buffer (pH 8.0) and incubated with 10 percent
normal horse serum for 10 minutes at room temperature.
Sections were then incubated overnight at 4C with mouse
monoclonal antibodies against hMLH1 protein (clone G168-
15; PharMingen, San Diego, California) at a 1:100 dilution.
Antibody binding was detected by incubating the sections at
room temperature with the peroxidase-labeled DAKO
Envision System (DAKO, Carpinteris, California) and using
FIGURE 1. Flow diagram of subcohort members and patients on whom the current analyses were based, Netherlands Cohort Study on Diet and
Cancer, 1986–1993. NCR, Netherlands Cancer Registry; PALGA, Pathologisch Anatomisch Landelijk Geautomatiseerd Archief; APC,
adenomatous polyposis coli; MCR, mutation cluster region; hMLH1, human mut-L homologue 1; GSTM1, glutathione-S-transferase M1; GSTT1,
glutathione-S-transferase T1.
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diaminobenzidine as a chromogen. Sections were counter-
stained with hematoxylin.
Lesions were considered to lack hMLH1 protein expres-
sion when unequivocal absence of nuclear staining of the
tumor epithelial cells was observed. Nuclear staining of
normal epithelial and stromal cells or lymphocytes served as
an internal positive control. Staining profiles were scored
independently by at least two observers and, in the case of
discordant results, discussed with a pathologist until con-
sensus was reached. hMLH1 expression could be deter-
mined in 724 of the 737 patients for whom tumor DNAwas
available.
TABLE 1. Distribution of subcohort members, colorectal cancer patients with and without a truncating mutation in the adenomatous
polyposis coli gene (APC stop), and patients with and without human mut-L homologue 1 expression according to various
sociodemographic and lifestyle factors, Netherlands Cohort Study on Diet and Cancer, 1986–1993y
Molecular characteristic of colorectal tumor
Subcohort
(n ¼ 2,948) Overall
(n ¼ 661)
APCz stop
(n ¼ 217)
No APC stop
(n ¼ 377)
hMLH1z
absent (n ¼ 56)
hMLH1 present
(n ¼ 594)
No. or
mean %
No. or
mean
%
No. or
mean
%
No. or
mean
%
No. or
mean
%
No. or
mean
%
Sublocalization
Colon 11 434 127 274 54 374
Rectosigmoid
junction 73 33 30 72
Rectum 1 154 57 73 2 148
Mean age (years) 61.3 (4.2)§ 62.8 (4.0)* 62.6 (4.2) 62.9 (4.1) 63.0 (4.5) 62.8 (4.0)
Sex (% male) 48 56* 59 54 43 57***
Family history of
colorectal cancer
(% positive) 6 11* 11 10 9 11
Mean body mass
index{ 25.1 (3.1) 25.5 (3.1)** 25.7 (3.1) 25.4 (3.2) 25.6 (3.4) 25.5 (3.1)
Mean alcohol
consumption
(g/day) 10.1 (14.1) 11.5 (15.0) 12.2 (16.4) 11.3 (14.8) 10.4 (16.8) 11.6 (14.8)
Physical activity
(minutes/day)
<30 608 21 136 21 56 26 63 17 13 25 122 21
30–<60 920 31 201 31 63 29 119 32 10 19 185 31
60–<90 598 21 142 22 42 20 85 23 9 17 129 22
90 789 27 174 27 53 25 105 28 21 40 150 25
Use of tobacco
products
Never smoker 1,036 35 206 31 68 31 118 31 18 32 186 31
Smoker
Cigarettes 1,468 50 323 49 111 51 179 47 31 55 288 48
Cigars 32 1 4 0.6 2 0.5 4 0.7
Pipes 5 0.2 2 0.3 1 0.5 1 0.3 2 0.3
Cigarettes and
pipes 63 2 12 2 4 2 6 2 12 2
Cigarettes and
cigars 179 6 60 9 17 8 36 10 4 7 53 9
Cigars and
pipes 14 0.4 5 0.8 2 0.9 3 0.8 5 0.8
All three
products 149 5 49 7 14 6 32 8 3 5 44 7
* p < 0.001; ** p < 0.005 (for comparisons between the colorectal cancer overall group and the subcohort, cases that were also subcohort members were
excluded from the subcohort group); *** p ¼ 0.04 (for comparison between patients without and with hMLH1 expression).
y Numbers are based on subcohort members and patients without missing data on family history of colorectal cancer or body mass index.
z APC, adenomatous polyposis coli; hMLH1, human mut-L homologue 1.
§ Numbers in parentheses, standard deviation.
{Weight (kg)/height (m)2.
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TABLE 2. Incidence rate ratios for colorectal cancer among persons with and without a truncating mutation in the adenomatous polyposis coli gene (APC stop) and persons
with and without human mut-L homologue 1 expression, according to cigarette smoking (categorical and continuous analyses), Netherlands Cohort Study on Diet and Cancer,
1986–1993
Cigarette
smoking
variable
Person-
years in
subcohort*
Molecular characteristic of colorectal tumor
Overall APCy stop No APC stop hMLH1y absent hMLH1 present
No. of
patients*
IRRy,z 95% CIy No. of
patients*
IRRz 95% CI No. of
patients*
IRRz 95% CI No. of
patients*
IRRz 95% CI No. of
patients*
IRRz 95% CI
Never tobacco
smoker 5,088 206 1.00§ 68 1.00§ 118 1.00§ 18 1.00§ 186 1.00§
Smoking status
Ex-smoker 4,992 298 1.30 1.03, 1.65 90 1.05 0.73, 1.49 180 1.49 1.10, 2.00 20 1.48 0.72, 3.05 270 1.26 0.98, 1.60
Current smoker 3,937 146 0.91 0.71, 1.18 56 0.91 0.62, 1.35 73 0.85 0.61, 1.18 18 1.79 0.90, 3.54 127 0.85 0.65, 1.11
Frequency
(cigarettes/day)
<5 1,096 47 1.02 0.71, 1.46 18 1.11 0.64, 1.91 26 1.02 0.64, 1.63 3 0.94 0.27, 3.24 43 1.00 0.69, 1.46
5–<10 1,353 50 0.91 0.59, 1.30 16 0.82 0.46, 1.46 27 0.89 0.56, 1.42 4 1.18 0.40, 3.52 45 0.87 0.60, 1.27
10–<15 1,705 84 1.10 0.80, 1.52 27 0.95 0.57, 1.61 51 1.25 0.85, 1.84 9 2.18 0.89, 5.30 73 1.01 0.72, 1.41
15–<20 1,278 61 1.16 0.82, 1.64 18 0.91 0.52, 1.60 33 1.18 0.76, 1.84 7 2.53 1.02, 6.30 53 1.06 0.74, 1.53
20–<25 1,593 76 1.15 0.83, 1.59 30 1.18 0.74, 1.90 36 1.03 0.67, 1.58 5 1.47 0.51, 4.23 69 1.09 0.78, 1.53
25 1,385 95 1.59 1.16, 2.17 26 1.10 0.66, 1.82 63 2.02 1.38, 2.96 7 2.41 0.92, 6.31 86 1.50 1.08, 1.53
p for trend 0.01 0.60 0.004 0.04 0.04
Increment
(5 cigarettes/
day) 1.07 1.03, 1.12 1.01 0.95, 1.08 1.11 1.05, 1.17 1.09 0.98, 1.21 1.07 1.02, 1.22
Duration (years)
<10 447 17 1.02 0.59, 1.78 7 1.20 0.53, 2.74 10 1.08 0.54, 2.18 2 1.71 0.39, 7.48 14 0.91 0.50, 1.66
10–<20 1,151 53 1.16 0.81, 1.64 12 0.70 0.37, 1.33 32 1.29 0.83, 2.00 3 1.05 0.30, 3.73 49 1.14 0.79, 1.65
20–<30 1,827 92 1.15 0.85, 1.55 29 0.98 0.61, 1.58 56 1.30 0.90, 1.88 5 1.07 0.40, 2.83 85 1.13 0.83, 1.54
30–<40 2,311 128 1.32 1.00, 1.73 43 1.18 0.78, 1.80 77 1.47 1.05, 2.07 14 2.50 1.15, 5.43 110 1.20 0.90, 1.60
40–<50 2,640 109 0.90 0.67, 1.20 41 0.89 0.57, 1.39 54 0.83 0.57, 1.21 10 1.51 0.64, 3.57 98 0.85 0.63, 1.15
50 370 38 1.45 0.93, 2.28 11 1.15 0.56, 2.37 21 1.47 0.84, 2.56 4 2.99 0.92, 9.71 34 1.37 0.86, 2.19
p for trend 0.49 0.88 0.61 0.05 0.86
Increment
(10 years) 1.02 0.96, 1.07 1.01 0.92, 1.10 1.01 0.94, 1.08 1.17 1.00, 1.37 1.00 0.95, 1.06
Age (years) at
ﬁrst exposure
<15 1,428 71 1.14 0.81, 1.62 23 1.03 0.60, 1.78 37 1.09 0.69, 1.71 3 0.94 0.25, 3.50 67 1.14 0.79, 1.64
15–<17 1,955 116 1.41 1.04, 1.92 45 1.53 0.97, 2.44 60 1.33 0.89, 1.97 9 2.02 0.82, 5.01 104 1.34 0.97, 1.85
17–<19 2,203 103 1.11 0.83, 1.50 36 1.09 0.68, 1.75 61 1.19 0.83, 1.72 11 1.98 0.83, 4.74 90 1.04 0.76, 1.42
19–<21 1,294 65 1.26 0.90, 1.77 17 0.94 0.54, 1.66 39 1.36 0.89, 2.07 6 1.84 0.74, 4.58 59 1.23 0.86, 1.75
21–<25 735 36 1.17 0.78, 1.77 11 1.05 0.54, 2.06 22 1.28 0.76, 2.13 3 1.47 0.41, 5.20 32 1.13 0.73, 1.74
25 1,185 44 0.87 0.61, 1.25 9 0.54 0.26, 1.10 30 1.04 0.68, 1.60 6 1.45 0.57, 3.69 36 0.79 0.53, 1.16
p for trendz 0.32 0.13 0.95 0.88 0.23
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GSTM1 and GSTT1 polymorphism analyses
A seminested multiplex PCR was performed for simul-
taneous assessment of the presence or absence of GSTM1
and GSTT1 alleles. Flank PCR was performed to generate
PCR products for GSTM1 and GSTT1 alleles and b-globin
using DNA derived from formalin-fixed paraffin-embedded
tumor tissue. In a 1:100 dilution, the flank PCR product
served as a template for a second round of PCR. In each
PCR, one round of 35 cycles was performed. Series positive
(b-globin amplification) and negative (no DNA) controls
were included in each PCR. The absence or presence and
length of PCR products of GSTM1 and GSTT1 alleles were
checked by electrophoresis on 2 percent agarose gels and
visualized with ethidium bromide. Reproducibility was
shown to be 91 percent (42/46).
Genotypes of GSTM1 or GSTT1 could not be determined
in 79 patients for whom tumor DNA was available. These
patients were excluded from this study.
Exposure assessment
In the questionnaire, tobacco smoking was addressed
through questions on ages at first and last exposure to
smoking, smoking frequency, smoking duration, and in-
halation for cigarette smokers, cigar smokers, and pipe
smokers. The dietary section of the 150-item semiquantita-
tive food frequency questionnaire concentrated on habitual
intake of foods and beverages, as well as lifestyle factors,
during the year preceding the start of the study.
Questionnaire data were key-entered twice and processed
for all incident cases in the cohort and for all subcohort
members in a manner blinded with respect to case/subcohort
status. Subjects whose dietary data were incomplete or
inconsistent (49 cases, two of whom were also subcohort
members, and 216 subcohort members) were excluded
from the analyses. Criteria used for this selection were 60
or more questionnaire items left blank, consumption of 35 or
more food items less than once per month, and/or one or
more item blocks (groups of items, such as beverages) left
blank. Eventually, 685 colorectal cancer patients (389 men,
296 women), of whom 12 were also subcohort members,
and 3,048 subcohort members (1,475 men and 1,573
women) were included in the analyses (figure 1).
Statistical analysis
The data analyses were conducted separately for overall
colorectal cancer, colorectal cancer with and without
a truncating APC mutation, tumors with a specific
C:G/T:A or G:C/T:A point mutation resulting in a stop
codon, and colorectal cancer with and without hMLH1
expression.
Using the Mann-Whitney U test or Student’s t test, we
analyzed differences in mean values for age at baseline
(years), alcohol intake (g/day), and body mass index
(weight (kg)/height (m)2) between all colorectal cancer
patients and subcohort members, between patients with
and without a truncating mutation in the mutation cluster
region of the APC gene, and between patients with absent
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and present hMLH1 expression. The distributions of sex,
family history of colorectal cancer (yes/no), and leisure-
time physical activity (<30, 30–60, 60–90, >90 minutes/
day) between all colorectal cancer patients, patients with
a truncating APCmutation, or patients with absent hMLH1
expression and subcohort members were tested using the
v2 test.
Incidence rate ratios (IRRs) for overall colorectal cancer
according to smoking frequency (cigarettes/day), smoking
duration (years), age at starting smoking (years), time since
smoking cessation (years), and corresponding continuous
variables, in comparison with lifelong nonsmoking, were
estimated using Cox proportional hazards regression mod-
els. In addition, associations were estimated for specific
tumor molecular endpoints.
Standard errors were estimated using the robust Huber-
White sandwich estimator to account for additional variance
introduced by sampling from the cohort (33). The pro-
portional hazards assumption was tested using the scaled
Schoenfeld residuals (34). Tests for dose-response trends
over the different categories of smoking variables were
estimated by fitting the ordinal exposure variables as
continuous terms and were evaluated using the Wald test.
For estimation of the p value for trend over the categories of
age at starting smoking and years since smoking cessation
and the corresponding continuous analyses, nonsmokers
were excluded.
Age (years) at baseline; sex; family history of colorectal
cancer (yes/no); intake of vegetables (g/day), fruit (g/day),
alcohol (g/day), coffee (cups/day), meat (g/day), fat (g/day),
dietary fiber (g/day), calcium (mg/day), and energy (kJ/
day); body mass index (kg/m2); and leisure-time physical
activity (<30, 30–60, 60–90, >90 minutes/day) were
considered as potential confounders. Variables that were
found to statistically significantly (p < 0.05) contribute to
the multivariate model of overall colorectal cancer (age at
baseline, sex, body mass index, and family history of
colorectal cancer) by means of the Wald test or that showed
a 10 percent influence on the IRR for colorectal cancer
were included as covariates in the multivariate analyses.
Adjustment for body mass index gave rise to missing values
in 100 subcohort members, 13 colon cancer cases, and six
rectal cancer cases (figure 1).
In order to estimate interaction with the GSTM1 and
GSTT1 genotypes, a case-only design was applied. Odds
ratios for interaction between the genotype at risk (GSTM1
or GSTT1 null genotype) and smoking variables were
obtained using logistic regression modeling. Adjustment
for family history of colorectal cancer did not alter assessed
odds ratios.
All p values reported are for a two-sided test; p values less
than 0.05 were considered statistically significant.
RESULTS
The presented multivariate-adjusted IRRs for colorectal
cancer according to smoking are based on 661 colorectal
cancer patients and 2,948 subcohort members (figure 1).
Smoking habits and general characteristics of the population
under study are shown in table 1. Colorectal cancer patients
were slightly older than subcohort members (62.8 years
vs. 61.3 years; p < 0.001) and were more often male (56
percent vs. 48 percent; p < 0.001). When we considered
specific molecular features of the colorectal tumors of these
patients, relatively more men were found to harbor a tumor
with hMLH1 expression than without (57 percent vs. 43
percent; p ¼ 0.04).
Multivariate-adjusted IRRs for overall colorectal cancer,
tumors with and without a truncating APC mutation, and
tumors with and without hMLH1 expression according to
the smoking variables are shown in table 2. Additional
adjustment for family history of colorectal cancer and body
mass index resulted in similar risk estimates as the age- and
sex-adjusted IRRs. Since smoking of cigars and pipes was
rare (table 1), only data on cigarette smoking are presented.
Ex-smokers were found to be at increased risk of overall
colorectal cancer in comparison with never smokers (IRR ¼
1.30, 95 percent confidence interval (CI): 1.03, 1.65),
whereas current smokers were not (IRR ¼ 0.91, 95 percent
CI: 0.71, 1.18). A high frequency of cigarette smoking was
associated with a moderately increased risk of colorectal
cancer (for an increment of five cigarettes/day, IRR ¼ 1.07,
95 percent CI: 1.03, 1.12). The Pearson correlation co-
efficient for the correlation between smoking frequency and
smoking duration was weak (r ¼ 0.22). Additional adjust-
ment for smoking duration slightly increased the estimated
IRR (per five-cigarette/day increment, IRR ¼ 1.08, 95
percent CI: 1.03, 1.14). Long-term smoking was not asso-
ciated with overall colorectal cancer risk (for a 10-year
increment in smoking duration, IRR ¼ 1.02, 95 percent
CI: 0.96, 1.07). These results were based on patients for
whom tumor DNA was available. Analysis of the patients
initially recognized within the cohort yielded results similar
to those presented here (data not shown).
Tests for interactions between sex and any of the smoking
characteristics used in this study did not produce statistically
significant results (p ¼ 0.16 and p ¼ 0.47 for smoking
frequency and duration, respectively). Therefore, results are
presented for men and women combined. When the
association between smoking frequency and colorectal
cancer was examined for men and women separately, no
association was observed in women, but IRRs for men were
similar to the observed overall IRRs.
When we considered APC mutation status, introduction
of a stop codon did not appear to be associated with any of
the smoking variables (table 2). Moreover, specific point
mutations in APC that would lead to the introduction of
a stop codon and could be expected to be associated with
cigarette smoking (i.e., G:C/A:T transitions (65 patients)
and G:C/T:A transversions (34 patients)) were also not
associated with any of the smoking variables, with two
exceptions: The categorical variable for age at starting
smoking was inversely associated with G:C/A:T muta-
tions (p for trend ¼ 0.03), but no statistically significant
association was observed for the continuous variable (data
not shown). Smoking cessation was associated with a re-
duced risk of colorectal tumors harboring a G:C/T:A
mutation (per 10 years of smoking cessation, IRR ¼ 0.53,
95 percent CI: 0.28, 0.99). In contrast, tumors not harboring
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a truncating APC mutation appeared to be associated with
former smoking but not with current smoking (for ex-
smokers vs. never smokers, IRR¼ 1.49, 95 percent CI: 1.10,
2.00; for current smokers vs. never smokers, IRR ¼ 0.85,
95 percent CI: 0.61, 1.18) or smoking frequency (per five-
cigarette/day increment, IRR ¼ 1.11, 95 percent CI: 1.05,
1.17).
Absent hMLH1 expression appears to occur almost
exclusively in patients without a truncating APC mutation.
Of 56 patients with absent hMLH1 expression, only five also
harbored a truncating APC mutation. When estimating
associations for smoking variables in the limited group of
patients with a tumor lacking hMLH1 expression, positive
associations, though not statistically significant, were found
for smoking status (for ex-smokers vs. never smokers, IRR¼
1.48, 95 percent CI: 0.72, 3.05; for current smokers vs. never
smokers, IRR ¼ 1.79, 95 percent CI: 0.90, 3.54), smoking
frequency (per five-cigarette/day increment, IRR ¼ 1.09,
95 percent CI: 0.98, 1.21), smoking duration (per 10-year
increment, IRR ¼ 1.17, 95 percent CI: 1.00, 1.37), and
inhalation (for inhalation vs. never smoking, IRR¼ 1.94, 95
percent CI: 0.94, 3.99) (table 2). When smoking frequency
and smoking duration were simultaneously included in the
analysis, risk ratios were smaller, and smoking duration was
found to be more influential than smoking frequency (per
five-cigarette/day increment in frequency, IRR ¼ 1.03,
95 percent CI: 0.91, 1.16; per 10-year increment in duration,
IRR ¼ 1.15, 95 percent CI: 0.97, 1.38).
Among patients with tumors that expressed hMLH1,
a similar, statistically significant positive association with
smoking frequency was observed (per five-cigarette/day
increment, IRR ¼ 1.07, 95 percent CI: 1.02, 1.22), but no
association with smoking duration was observed (per 10-
year increment, IRR ¼ 1.00, 95 percent CI: 0.95, 1.06).
Table 3 presents odds ratios for interaction between the
GSTM1 and GSTT1 null genotypes and all smoking
variables for overall colorectal cancer, as determined in
the case-only design. A borderline-significant (p ¼ 0.06)
interaction was observed between the GSTM1 null genotype
and smoking frequency (for GSTM1 absence and an in-
crement of five cigarettes/day, the odds ratio for interaction
was 1.07 (95 percent CI: 1.00, 1.14)) but not with theGSTT1
null genotype and any of the smoking characteristics.
DISCUSSION
Among colorectal cancer patients from a large prospec-
tive cohort study in the Netherlands, we investigated the
associations between cigarette smoking characteristics and
overall colorectal cancer, tumors with and without specific
APC mutations, and tumors with and without hMLH1
expression. Moreover, we examined interactions between
smoking and the GSTM1 and GSTT1 genotypes. Of the
smoking characteristics examined in this study, cigarette
smoking, mainly the number of cigarettes smoked per day
(frequency), was found to be associated with an increased
risk of colorectal cancer. This association was most pro-
nounced in tumors without a truncating APC mutation. It
was also observed in tumors lacking hMLH1 expression, but
the latter were mainly associated with long-term smoking.
No statistically significant interactions between the GSTM1
or GSTT1 null genotype and smoking frequency were
observed.
TABLE 3. Odds ratios for interaction between smoking and the glutathione-S-transferase M1 and T1 genotypes in the estimated risk
of colorectal cancer, Netherlands Cohort Study on Diet and Cancer, 1986–1993*
Cigarette smoking variable
GSTM1y absent (n ¼ 266 (45%)) vs.
GSTM1 present (n ¼ 320 (55%))
GSTT1y absent (n ¼ 121 (21%)) vs.
GSTT1 present (n ¼ 465 (79%))
ORiy 95% CIy ORi 95% CI
Smoking status
Ex-smoker 1.18 0.81, 1.72 0.78 0.50, 1.23
Current smoker 1.13 0.72, 1.79 0.69 0.39, 1.22
Frequency (5 cigarettes/day) 1.07 1.00, 1.14 0.95 0.87, 1.04
Duration (10 years) 1.00 0.91, 1.09 0.95 0.87, 1.05
Age (years) at ﬁrst exposurez 0.98 0.86, 1.12 1.03 0.90, 1.17
Years since cessation (10 years)z 1.00 0.77, 1.29 1.01 0.98, 1.04
Inhalation
Yes 1.35 0.93, 1.96 0.80 0.51, 1.24
No 0.71 0.42, 1.17 0.62 0.33, 1.17
Filter usage
Filter-tipped 1.47 0.90, 2.42 0.68 0.36, 1.26
Non-ﬁlter-tipped 1.15 0.77, 1.73 0.96 0.60, 1.54
* Results were based on subjects without missing values for family history of colorectal cancer and body mass index (weight (kg)/height (m)2).
y GSTM1, glutathione-S-transferase M1; GSTT1, glutathione-S-transferase T1; ORi, odds ratio for interaction; CI, conﬁdence interval.
z Lifelong nonsmokers were excluded from the analysis.
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In the questionnaire used in this study, questions retro-
spectively covered a period long enough for detection of
possible associations, since the suggested induction time of
30–45 years (3) was met in most cases. The relative
importance of dose and duration of cigarette smoking
remains somewhat in question, because these parameters
are correlated. In this study, correlation between the two
characteristics was found to be rather low (r ¼ 0.22), and
correcting smoking frequency for duration did not alter risk
estimates much. For the association between cigarette
smoking and overall colorectal cancer, frequency appeared
to be more influential than duration. This is in accordance
with previous studies that have also found that dose, or
amount usually smoked per day, is an important predictor of
risk (35). It seems plausible that the absolute daily quantity
of carcinogens from cigarettes delivered to the colorectal
epithelium is important in producing mutations at a suffi-
ciently high rate.
In accordance with a case-control study in which no
association between cigarette smoking and truncating
APC mutations was observed (23), we did not observe an
association between cigarette smoking and truncating
mutations in the APC gene. The associations observed for
specific point mutations leading to truncation may be chance
findings and require confirmation in another study.
Cigarette smoking appeared to be associated with tumors
without a truncating APCmutation. Some tumors that do not
harbor truncating APC mutations lack hMLH1 expression.
We observed positive associations between smoking fre-
quency and (especially) smoking duration and colorectal
cancer without hMLH1 expression. This is in agreement
with case-control studies that have found cigarette smoking
to be associated with microsatellite instability in colon (20)
and colorectal (21, 22) tumors but not with another report
(23). Cigarette smoking may directly affect the methylation
of the hMLH1 promoter region, resulting in absent hMLH1
expression and hence deficient DNA repair (21). On the
other hand, cigarette smoke contains numerous carcino-
genic compounds that may cause mutations. When DNA
repair mechanisms fail (e.g., by lack of hMLH1 expression),
tumors may become more susceptible to mutations that
could eventually lead to carcinoma.
Polymorphisms in the genotype of the carcinogen me-
tabolizing glutathione-S-transferases may alter colorectal
cancer risk. One study found a borderline-significant two-
fold elevated risk associated with the GSTM1 null genotype
and cigarette smoking in comparison with never smokers
who had the GSTM1 present genotype for rectal cancer in
men (28) but not for colon cancer (26). No interaction was
found for GSTM1 in colon adenomas (24) or for GSTM1 and
GSTT1 in colorectal cancer (25, 27).
A valid interpretation of the interaction parameter as
estimated from a case-only study requires the assumption
of independence between the gene polymorphism and
exposure in the population (36, 37). In a large group of
controls from the database of the International Collaborative
Study on Genetic Susceptibility to Environmental Carci-
nogens, it was shown that there was no association between
smoking and the GSTM1 or GSTT1 genotype (38). We did
not observe statistically significant interactions between
GSTM1 or GSTT1 and any of the smoking variables. A
borderline-significant interaction between smoking fre-
quency and GSTM1 genotype was observed. Although the
odds ratio for interaction between the GSTM1 genotype and
smoking frequency is difficult to interpret in the absence of
information on the colorectal cancer risk conferred by the
GSTM1 null genotype per se, the effect of GSTM1 genotype
on cigarette smoking seems negligible. Because of the
limited number of tumors displaying hMLH1 deficiency, no
interaction of the GSTM1 and GSTT1 genotypes in this
potentially interesting group could be estimated.
Although associations studied here were hypothesis-
based, studying the different subsets of tumors resulted in
multiple testing, which may have given rise to chance
findings. The statistically significant results observed for
overall colorectal cancer in this study are in accordance with
results from other studies (3). The absence of hMLH1 is
a rare occurrence in sporadic colorectal cancer; therefore,
just 53 patients were available in our reasonably large cohort
for studying associations between cigarette smoking and
risk of colorectal tumors without hMLH1 expression. This
limited number of patients may have given rise to spurious
findings, but the observed associations for hMLH1-deficient
tumors are also in keeping with previous reports on colon
cancer (20–22).
This study indicates that cigarette smoking may contrib-
ute to colorectal cancer. The association between frequency
of cigarette smoking and colorectal cancer is most apparent
in cancers that do not harbor a truncating mutation in the
APC gene. Duration of smoking was associated with
hMLH1-deficient tumors, though estimated risk ratios were
moderate and their corresponding confidence intervals were
wide. Finally, modification of the effect of cigarette
smoking by the GSTM1 and GSTT1 null genotypes seems
negligible.
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